nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—HTR2A—vein—ovarian cancer	0.00745	0.108	CbGeAlD
Pramipexole—DRD4—testis—ovarian cancer	0.00352	0.0509	CbGeAlD
Pramipexole—DRD5—female reproductive system—ovarian cancer	0.00287	0.0415	CbGeAlD
Pramipexole—HTR2B—myometrium—ovarian cancer	0.00274	0.0397	CbGeAlD
Pramipexole—DRD5—female gonad—ovarian cancer	0.00261	0.0378	CbGeAlD
Pramipexole—ADRA2C—myometrium—ovarian cancer	0.00216	0.0313	CbGeAlD
Pramipexole—HTR2B—uterine cervix—ovarian cancer	0.00214	0.0309	CbGeAlD
Pramipexole—HTR2B—decidua—ovarian cancer	0.00203	0.0294	CbGeAlD
Pramipexole—HTR2B—endometrium—ovarian cancer	0.00193	0.0279	CbGeAlD
Pramipexole—HTR2B—uterus—ovarian cancer	0.00178	0.0258	CbGeAlD
Pramipexole—HTR1B—female reproductive system—ovarian cancer	0.00178	0.0257	CbGeAlD
Pramipexole—ADRA2A—myometrium—ovarian cancer	0.00172	0.0249	CbGeAlD
Pramipexole—HTR1D—female reproductive system—ovarian cancer	0.00172	0.0249	CbGeAlD
Pramipexole—HTR2C—female reproductive system—ovarian cancer	0.0017	0.0246	CbGeAlD
Pramipexole—ADRA2C—uterine cervix—ovarian cancer	0.00168	0.0243	CbGeAlD
Pramipexole—ADRA2C—decidua—ovarian cancer	0.0016	0.0232	CbGeAlD
Pramipexole—HTR2B—female reproductive system—ovarian cancer	0.0016	0.0231	CbGeAlD
Pramipexole—SLC22A1—vagina—ovarian cancer	0.00157	0.0227	CbGeAlD
Pramipexole—ADRA2C—endometrium—ovarian cancer	0.00152	0.022	CbGeAlD
Pramipexole—HTR2B—vagina—ovarian cancer	0.00145	0.0209	CbGeAlD
Pramipexole—HTR2A—embryo—ovarian cancer	0.00141	0.0204	CbGeAlD
Pramipexole—ADRA2C—uterus—ovarian cancer	0.0014	0.0203	CbGeAlD
Pramipexole—ADRA2A—uterine cervix—ovarian cancer	0.00134	0.0194	CbGeAlD
Pramipexole—ADRA2A—decidua—ovarian cancer	0.00128	0.0185	CbGeAlD
Pramipexole—ADRA2A—endometrium—ovarian cancer	0.00121	0.0176	CbGeAlD
Pramipexole—HTR2A—epithelium—ovarian cancer	0.00115	0.0166	CbGeAlD
Pramipexole—ADRA2C—female gonad—ovarian cancer	0.00115	0.0166	CbGeAlD
Pramipexole—ADRA2C—vagina—ovarian cancer	0.00114	0.0165	CbGeAlD
Pramipexole—ADRA2A—gonad—ovarian cancer	0.00113	0.0163	CbGeAlD
Pramipexole—ADRA2A—uterus—ovarian cancer	0.00112	0.0162	CbGeAlD
Pramipexole—DRD2—testis—ovarian cancer	0.00105	0.0151	CbGeAlD
Pramipexole—ADRA2C—testis—ovarian cancer	0.00102	0.0147	CbGeAlD
Pramipexole—ADRA2A—female reproductive system—ovarian cancer	0.001	0.0145	CbGeAlD
Pramipexole—HTR2A—gonad—ovarian cancer	0.000957	0.0138	CbGeAlD
Pramipexole—HTR2B—lymph node—ovarian cancer	0.000936	0.0135	CbGeAlD
Pramipexole—ADRA2A—female gonad—ovarian cancer	0.000914	0.0132	CbGeAlD
Pramipexole—ADRA2A—vagina—ovarian cancer	0.000909	0.0131	CbGeAlD
Pramipexole—HTR2A—female reproductive system—ovarian cancer	0.000854	0.0124	CbGeAlD
Pramipexole—ADRA2A—testis—ovarian cancer	0.000811	0.0117	CbGeAlD
Pramipexole—HTR2A—vagina—ovarian cancer	0.000773	0.0112	CbGeAlD
Pramipexole—ADRA2C—lymph node—ovarian cancer	0.000737	0.0107	CbGeAlD
Pramipexole—HTR2A—testis—ovarian cancer	0.00069	0.00998	CbGeAlD
Pramipexole—ADRA2A—lymph node—ovarian cancer	0.000588	0.0085	CbGeAlD
Pramipexole—Urinary tract infection—Epirubicin—ovarian cancer	0.000274	0.000299	CcSEcCtD
Pramipexole—Dysuria—Doxorubicin—ovarian cancer	0.000274	0.000299	CcSEcCtD
Pramipexole—Decreased appetite—Paclitaxel—ovarian cancer	0.000273	0.000299	CcSEcCtD
Pramipexole—Dry mouth—Docetaxel—ovarian cancer	0.000272	0.000297	CcSEcCtD
Pramipexole—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000272	0.000297	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000272	0.000297	CcSEcCtD
Pramipexole—Fatigue—Paclitaxel—ovarian cancer	0.000271	0.000296	CcSEcCtD
Pramipexole—Sweating—Epirubicin—ovarian cancer	0.00027	0.000295	CcSEcCtD
Pramipexole—Pollakiuria—Doxorubicin—ovarian cancer	0.00027	0.000295	CcSEcCtD
Pramipexole—Constipation—Paclitaxel—ovarian cancer	0.000269	0.000294	CcSEcCtD
Pramipexole—Pain—Paclitaxel—ovarian cancer	0.000269	0.000294	CcSEcCtD
Pramipexole—Haematuria—Epirubicin—ovarian cancer	0.000269	0.000294	CcSEcCtD
Pramipexole—Confusional state—Docetaxel—ovarian cancer	0.000269	0.000294	CcSEcCtD
Pramipexole—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000267	0.000292	CcSEcCtD
Pramipexole—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000267	0.000291	CcSEcCtD
Pramipexole—Oedema—Docetaxel—ovarian cancer	0.000267	0.000291	CcSEcCtD
Pramipexole—Weight increased—Doxorubicin—ovarian cancer	0.000266	0.000291	CcSEcCtD
Pramipexole—Epistaxis—Epirubicin—ovarian cancer	0.000266	0.00029	CcSEcCtD
Pramipexole—Infection—Docetaxel—ovarian cancer	0.000265	0.000289	CcSEcCtD
Pramipexole—Weight decreased—Doxorubicin—ovarian cancer	0.000265	0.000289	CcSEcCtD
Pramipexole—Sinusitis—Epirubicin—ovarian cancer	0.000264	0.000289	CcSEcCtD
Pramipexole—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000264	0.000288	CcSEcCtD
Pramipexole—Pneumonia—Doxorubicin—ovarian cancer	0.000262	0.000287	CcSEcCtD
Pramipexole—Shock—Docetaxel—ovarian cancer	0.000262	0.000286	CcSEcCtD
Pramipexole—Nervous system disorder—Docetaxel—ovarian cancer	0.000261	0.000285	CcSEcCtD
Pramipexole—Thrombocytopenia—Docetaxel—ovarian cancer	0.000261	0.000285	CcSEcCtD
Pramipexole—Drowsiness—Doxorubicin—ovarian cancer	0.000261	0.000285	CcSEcCtD
Pramipexole—Infestation NOS—Doxorubicin—ovarian cancer	0.000261	0.000285	CcSEcCtD
Pramipexole—Infestation—Doxorubicin—ovarian cancer	0.000261	0.000285	CcSEcCtD
Pramipexole—Tachycardia—Docetaxel—ovarian cancer	0.00026	0.000284	CcSEcCtD
Pramipexole—Feeling abnormal—Paclitaxel—ovarian cancer	0.000259	0.000283	CcSEcCtD
Pramipexole—Skin disorder—Docetaxel—ovarian cancer	0.000259	0.000283	CcSEcCtD
Pramipexole—Bradycardia—Epirubicin—ovarian cancer	0.000258	0.000281	CcSEcCtD
Pramipexole—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000257	0.000281	CcSEcCtD
Pramipexole—Renal failure—Doxorubicin—ovarian cancer	0.000256	0.00028	CcSEcCtD
Pramipexole—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000256	0.000279	CcSEcCtD
Pramipexole—Anorexia—Docetaxel—ovarian cancer	0.000254	0.000277	CcSEcCtD
Pramipexole—Rhinitis—Epirubicin—ovarian cancer	0.000254	0.000277	CcSEcCtD
Pramipexole—Urinary tract infection—Doxorubicin—ovarian cancer	0.000254	0.000277	CcSEcCtD
Pramipexole—Conjunctivitis—Doxorubicin—ovarian cancer	0.000254	0.000277	CcSEcCtD
Pramipexole—Hypoaesthesia—Epirubicin—ovarian cancer	0.000252	0.000275	CcSEcCtD
Pramipexole—Pharyngitis—Epirubicin—ovarian cancer	0.000251	0.000274	CcSEcCtD
Pramipexole—Sweating—Doxorubicin—ovarian cancer	0.00025	0.000273	CcSEcCtD
Pramipexole—Urinary tract disorder—Epirubicin—ovarian cancer	0.00025	0.000273	CcSEcCtD
Pramipexole—Urticaria—Paclitaxel—ovarian cancer	0.00025	0.000273	CcSEcCtD
Pramipexole—Oedema peripheral—Epirubicin—ovarian cancer	0.000249	0.000272	CcSEcCtD
Pramipexole—Hypotension—Docetaxel—ovarian cancer	0.000249	0.000272	CcSEcCtD
Pramipexole—Haematuria—Doxorubicin—ovarian cancer	0.000249	0.000272	CcSEcCtD
Pramipexole—Connective tissue disorder—Epirubicin—ovarian cancer	0.000249	0.000272	CcSEcCtD
Pramipexole—Body temperature increased—Paclitaxel—ovarian cancer	0.000249	0.000271	CcSEcCtD
Pramipexole—Abdominal pain—Paclitaxel—ovarian cancer	0.000249	0.000271	CcSEcCtD
Pramipexole—Urethral disorder—Epirubicin—ovarian cancer	0.000248	0.000271	CcSEcCtD
Pramipexole—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000247	0.000269	CcSEcCtD
Pramipexole—Epistaxis—Doxorubicin—ovarian cancer	0.000246	0.000269	CcSEcCtD
Pramipexole—Sinusitis—Doxorubicin—ovarian cancer	0.000245	0.000267	CcSEcCtD
Pramipexole—Visual impairment—Epirubicin—ovarian cancer	0.000244	0.000266	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000243	0.000265	CcSEcCtD
Pramipexole—Insomnia—Docetaxel—ovarian cancer	0.000241	0.000263	CcSEcCtD
Pramipexole—Paraesthesia—Docetaxel—ovarian cancer	0.000239	0.000261	CcSEcCtD
Pramipexole—Bradycardia—Doxorubicin—ovarian cancer	0.000238	0.00026	CcSEcCtD
Pramipexole—Dyspnoea—Docetaxel—ovarian cancer	0.000238	0.00026	CcSEcCtD
Pramipexole—Somnolence—Docetaxel—ovarian cancer	0.000237	0.000259	CcSEcCtD
Pramipexole—Eye disorder—Epirubicin—ovarian cancer	0.000237	0.000258	CcSEcCtD
Pramipexole—Tinnitus—Epirubicin—ovarian cancer	0.000236	0.000258	CcSEcCtD
Pramipexole—Cardiac disorder—Epirubicin—ovarian cancer	0.000235	0.000256	CcSEcCtD
Pramipexole—Flushing—Epirubicin—ovarian cancer	0.000235	0.000256	CcSEcCtD
Pramipexole—Rhinitis—Doxorubicin—ovarian cancer	0.000235	0.000256	CcSEcCtD
Pramipexole—Dyspepsia—Docetaxel—ovarian cancer	0.000235	0.000256	CcSEcCtD
Pramipexole—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000233	0.000254	CcSEcCtD
Pramipexole—Pharyngitis—Doxorubicin—ovarian cancer	0.000232	0.000254	CcSEcCtD
Pramipexole—Decreased appetite—Docetaxel—ovarian cancer	0.000232	0.000253	CcSEcCtD
Pramipexole—Hypersensitivity—Paclitaxel—ovarian cancer	0.000232	0.000253	CcSEcCtD
Pramipexole—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000231	0.000253	CcSEcCtD
Pramipexole—Oedema peripheral—Doxorubicin—ovarian cancer	0.000231	0.000252	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00023	0.000251	CcSEcCtD
Pramipexole—Connective tissue disorder—Doxorubicin—ovarian cancer	0.00023	0.000251	CcSEcCtD
Pramipexole—Fatigue—Docetaxel—ovarian cancer	0.00023	0.000251	CcSEcCtD
Pramipexole—Angiopathy—Epirubicin—ovarian cancer	0.00023	0.000251	CcSEcCtD
Pramipexole—Urethral disorder—Doxorubicin—ovarian cancer	0.00023	0.000251	CcSEcCtD
Pramipexole—Immune system disorder—Epirubicin—ovarian cancer	0.000229	0.00025	CcSEcCtD
Pramipexole—Mediastinal disorder—Epirubicin—ovarian cancer	0.000228	0.000249	CcSEcCtD
Pramipexole—Constipation—Docetaxel—ovarian cancer	0.000228	0.000249	CcSEcCtD
Pramipexole—Pain—Docetaxel—ovarian cancer	0.000228	0.000249	CcSEcCtD
Pramipexole—Chills—Epirubicin—ovarian cancer	0.000227	0.000248	CcSEcCtD
Pramipexole—Visual impairment—Doxorubicin—ovarian cancer	0.000226	0.000246	CcSEcCtD
Pramipexole—Asthenia—Paclitaxel—ovarian cancer	0.000226	0.000246	CcSEcCtD
Pramipexole—Alopecia—Epirubicin—ovarian cancer	0.000224	0.000244	CcSEcCtD
Pramipexole—Pruritus—Paclitaxel—ovarian cancer	0.000223	0.000243	CcSEcCtD
Pramipexole—Mental disorder—Epirubicin—ovarian cancer	0.000222	0.000242	CcSEcCtD
Pramipexole—Erythema—Epirubicin—ovarian cancer	0.00022	0.000241	CcSEcCtD
Pramipexole—Malnutrition—Epirubicin—ovarian cancer	0.00022	0.000241	CcSEcCtD
Pramipexole—Feeling abnormal—Docetaxel—ovarian cancer	0.00022	0.00024	CcSEcCtD
Pramipexole—Eye disorder—Doxorubicin—ovarian cancer	0.000219	0.000239	CcSEcCtD
Pramipexole—Tinnitus—Doxorubicin—ovarian cancer	0.000218	0.000238	CcSEcCtD
Pramipexole—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000218	0.000238	CcSEcCtD
Pramipexole—Flushing—Doxorubicin—ovarian cancer	0.000217	0.000237	CcSEcCtD
Pramipexole—Cardiac disorder—Doxorubicin—ovarian cancer	0.000217	0.000237	CcSEcCtD
Pramipexole—Flatulence—Epirubicin—ovarian cancer	0.000217	0.000237	CcSEcCtD
Pramipexole—Tension—Epirubicin—ovarian cancer	0.000216	0.000236	CcSEcCtD
Pramipexole—Dysgeusia—Epirubicin—ovarian cancer	0.000216	0.000236	CcSEcCtD
Pramipexole—Diarrhoea—Paclitaxel—ovarian cancer	0.000215	0.000235	CcSEcCtD
Pramipexole—Nervousness—Epirubicin—ovarian cancer	0.000214	0.000234	CcSEcCtD
Pramipexole—Back pain—Epirubicin—ovarian cancer	0.000213	0.000233	CcSEcCtD
Pramipexole—Angiopathy—Doxorubicin—ovarian cancer	0.000212	0.000232	CcSEcCtD
Pramipexole—Muscle spasms—Epirubicin—ovarian cancer	0.000212	0.000231	CcSEcCtD
Pramipexole—Immune system disorder—Doxorubicin—ovarian cancer	0.000212	0.000231	CcSEcCtD
Pramipexole—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000211	0.00023	CcSEcCtD
Pramipexole—Body temperature increased—Docetaxel—ovarian cancer	0.000211	0.00023	CcSEcCtD
Pramipexole—Abdominal pain—Docetaxel—ovarian cancer	0.000211	0.00023	CcSEcCtD
Pramipexole—Chills—Doxorubicin—ovarian cancer	0.00021	0.000229	CcSEcCtD
Pramipexole—Dizziness—Paclitaxel—ovarian cancer	0.000208	0.000227	CcSEcCtD
Pramipexole—Vision blurred—Epirubicin—ovarian cancer	0.000208	0.000227	CcSEcCtD
Pramipexole—Alopecia—Doxorubicin—ovarian cancer	0.000207	0.000226	CcSEcCtD
Pramipexole—Mental disorder—Doxorubicin—ovarian cancer	0.000205	0.000224	CcSEcCtD
Pramipexole—Ill-defined disorder—Epirubicin—ovarian cancer	0.000204	0.000223	CcSEcCtD
Pramipexole—Erythema—Doxorubicin—ovarian cancer	0.000204	0.000223	CcSEcCtD
Pramipexole—Malnutrition—Doxorubicin—ovarian cancer	0.000204	0.000223	CcSEcCtD
Pramipexole—Anaemia—Epirubicin—ovarian cancer	0.000204	0.000222	CcSEcCtD
Pramipexole—Agitation—Epirubicin—ovarian cancer	0.000202	0.000221	CcSEcCtD
Pramipexole—Flatulence—Doxorubicin—ovarian cancer	0.000201	0.000219	CcSEcCtD
Pramipexole—Tension—Doxorubicin—ovarian cancer	0.0002	0.000218	CcSEcCtD
Pramipexole—Vomiting—Paclitaxel—ovarian cancer	0.0002	0.000218	CcSEcCtD
Pramipexole—Dysgeusia—Doxorubicin—ovarian cancer	0.0002	0.000218	CcSEcCtD
Pramipexole—Malaise—Epirubicin—ovarian cancer	0.000199	0.000217	CcSEcCtD
Pramipexole—Rash—Paclitaxel—ovarian cancer	0.000198	0.000217	CcSEcCtD
Pramipexole—Dermatitis—Paclitaxel—ovarian cancer	0.000198	0.000216	CcSEcCtD
Pramipexole—Nervousness—Doxorubicin—ovarian cancer	0.000198	0.000216	CcSEcCtD
Pramipexole—Vertigo—Epirubicin—ovarian cancer	0.000198	0.000216	CcSEcCtD
Pramipexole—Syncope—Epirubicin—ovarian cancer	0.000198	0.000216	CcSEcCtD
Pramipexole—Leukopenia—Epirubicin—ovarian cancer	0.000197	0.000215	CcSEcCtD
Pramipexole—Back pain—Doxorubicin—ovarian cancer	0.000197	0.000215	CcSEcCtD
Pramipexole—Headache—Paclitaxel—ovarian cancer	0.000197	0.000215	CcSEcCtD
Pramipexole—Hypersensitivity—Docetaxel—ovarian cancer	0.000196	0.000214	CcSEcCtD
Pramipexole—Muscle spasms—Doxorubicin—ovarian cancer	0.000196	0.000214	CcSEcCtD
Pramipexole—Palpitations—Epirubicin—ovarian cancer	0.000195	0.000213	CcSEcCtD
Pramipexole—Loss of consciousness—Epirubicin—ovarian cancer	0.000194	0.000211	CcSEcCtD
Pramipexole—Cough—Epirubicin—ovarian cancer	0.000192	0.00021	CcSEcCtD
Pramipexole—Vision blurred—Doxorubicin—ovarian cancer	0.000192	0.00021	CcSEcCtD
Pramipexole—Asthenia—Docetaxel—ovarian cancer	0.000191	0.000209	CcSEcCtD
Pramipexole—Convulsion—Epirubicin—ovarian cancer	0.000191	0.000208	CcSEcCtD
Pramipexole—Hypertension—Epirubicin—ovarian cancer	0.00019	0.000208	CcSEcCtD
Pramipexole—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000189	0.000207	CcSEcCtD
Pramipexole—Pruritus—Docetaxel—ovarian cancer	0.000189	0.000206	CcSEcCtD
Pramipexole—Anaemia—Doxorubicin—ovarian cancer	0.000188	0.000206	CcSEcCtD
Pramipexole—Chest pain—Epirubicin—ovarian cancer	0.000188	0.000205	CcSEcCtD
Pramipexole—Myalgia—Epirubicin—ovarian cancer	0.000188	0.000205	CcSEcCtD
Pramipexole—Arthralgia—Epirubicin—ovarian cancer	0.000188	0.000205	CcSEcCtD
Pramipexole—Agitation—Doxorubicin—ovarian cancer	0.000187	0.000205	CcSEcCtD
Pramipexole—Anxiety—Epirubicin—ovarian cancer	0.000187	0.000204	CcSEcCtD
Pramipexole—Nausea—Paclitaxel—ovarian cancer	0.000187	0.000204	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000186	0.000203	CcSEcCtD
Pramipexole—Discomfort—Epirubicin—ovarian cancer	0.000185	0.000202	CcSEcCtD
Pramipexole—Malaise—Doxorubicin—ovarian cancer	0.000184	0.000201	CcSEcCtD
Pramipexole—Dry mouth—Epirubicin—ovarian cancer	0.000183	0.0002	CcSEcCtD
Pramipexole—Vertigo—Doxorubicin—ovarian cancer	0.000183	0.0002	CcSEcCtD
Pramipexole—Syncope—Doxorubicin—ovarian cancer	0.000183	0.0002	CcSEcCtD
Pramipexole—Leukopenia—Doxorubicin—ovarian cancer	0.000182	0.000199	CcSEcCtD
Pramipexole—Diarrhoea—Docetaxel—ovarian cancer	0.000182	0.000199	CcSEcCtD
Pramipexole—Confusional state—Epirubicin—ovarian cancer	0.000181	0.000198	CcSEcCtD
Pramipexole—Palpitations—Doxorubicin—ovarian cancer	0.00018	0.000197	CcSEcCtD
Pramipexole—Oedema—Epirubicin—ovarian cancer	0.00018	0.000196	CcSEcCtD
Pramipexole—Loss of consciousness—Doxorubicin—ovarian cancer	0.000179	0.000196	CcSEcCtD
Pramipexole—Infection—Epirubicin—ovarian cancer	0.000179	0.000195	CcSEcCtD
Pramipexole—Cough—Doxorubicin—ovarian cancer	0.000178	0.000194	CcSEcCtD
Pramipexole—Shock—Epirubicin—ovarian cancer	0.000177	0.000193	CcSEcCtD
Pramipexole—Convulsion—Doxorubicin—ovarian cancer	0.000177	0.000193	CcSEcCtD
Pramipexole—Nervous system disorder—Epirubicin—ovarian cancer	0.000176	0.000193	CcSEcCtD
Pramipexole—Dizziness—Docetaxel—ovarian cancer	0.000176	0.000192	CcSEcCtD
Pramipexole—Thrombocytopenia—Epirubicin—ovarian cancer	0.000176	0.000192	CcSEcCtD
Pramipexole—Hypertension—Doxorubicin—ovarian cancer	0.000176	0.000192	CcSEcCtD
Pramipexole—Tachycardia—Epirubicin—ovarian cancer	0.000175	0.000192	CcSEcCtD
Pramipexole—Skin disorder—Epirubicin—ovarian cancer	0.000175	0.000191	CcSEcCtD
Pramipexole—Hyperhidrosis—Epirubicin—ovarian cancer	0.000174	0.00019	CcSEcCtD
Pramipexole—Chest pain—Doxorubicin—ovarian cancer	0.000174	0.00019	CcSEcCtD
Pramipexole—Arthralgia—Doxorubicin—ovarian cancer	0.000174	0.00019	CcSEcCtD
Pramipexole—Myalgia—Doxorubicin—ovarian cancer	0.000174	0.00019	CcSEcCtD
Pramipexole—Anxiety—Doxorubicin—ovarian cancer	0.000173	0.000189	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000172	0.000188	CcSEcCtD
Pramipexole—Discomfort—Doxorubicin—ovarian cancer	0.000171	0.000187	CcSEcCtD
Pramipexole—Anorexia—Epirubicin—ovarian cancer	0.000171	0.000187	CcSEcCtD
Pramipexole—Dry mouth—Doxorubicin—ovarian cancer	0.00017	0.000185	CcSEcCtD
Pramipexole—Vomiting—Docetaxel—ovarian cancer	0.000169	0.000185	CcSEcCtD
Pramipexole—Rash—Docetaxel—ovarian cancer	0.000168	0.000184	CcSEcCtD
Pramipexole—Hypotension—Epirubicin—ovarian cancer	0.000168	0.000183	CcSEcCtD
Pramipexole—Dermatitis—Docetaxel—ovarian cancer	0.000168	0.000183	CcSEcCtD
Pramipexole—Confusional state—Doxorubicin—ovarian cancer	0.000168	0.000183	CcSEcCtD
Pramipexole—Headache—Docetaxel—ovarian cancer	0.000167	0.000182	CcSEcCtD
Pramipexole—Oedema—Doxorubicin—ovarian cancer	0.000166	0.000182	CcSEcCtD
Pramipexole—Infection—Doxorubicin—ovarian cancer	0.000165	0.00018	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000164	0.000179	CcSEcCtD
Pramipexole—Shock—Doxorubicin—ovarian cancer	0.000164	0.000179	CcSEcCtD
Pramipexole—Nervous system disorder—Doxorubicin—ovarian cancer	0.000163	0.000178	CcSEcCtD
Pramipexole—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000163	0.000178	CcSEcCtD
Pramipexole—Insomnia—Epirubicin—ovarian cancer	0.000163	0.000178	CcSEcCtD
Pramipexole—Tachycardia—Doxorubicin—ovarian cancer	0.000162	0.000177	CcSEcCtD
Pramipexole—Skin disorder—Doxorubicin—ovarian cancer	0.000162	0.000176	CcSEcCtD
Pramipexole—Paraesthesia—Epirubicin—ovarian cancer	0.000161	0.000176	CcSEcCtD
Pramipexole—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000161	0.000176	CcSEcCtD
Pramipexole—Dyspnoea—Epirubicin—ovarian cancer	0.00016	0.000175	CcSEcCtD
Pramipexole—Somnolence—Epirubicin—ovarian cancer	0.00016	0.000175	CcSEcCtD
Pramipexole—Anorexia—Doxorubicin—ovarian cancer	0.000159	0.000173	CcSEcCtD
Pramipexole—Nausea—Docetaxel—ovarian cancer	0.000158	0.000173	CcSEcCtD
Pramipexole—Dyspepsia—Epirubicin—ovarian cancer	0.000158	0.000173	CcSEcCtD
Pramipexole—Decreased appetite—Epirubicin—ovarian cancer	0.000156	0.000171	CcSEcCtD
Pramipexole—Hypotension—Doxorubicin—ovarian cancer	0.000155	0.00017	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000155	0.00017	CcSEcCtD
Pramipexole—Fatigue—Epirubicin—ovarian cancer	0.000155	0.000169	CcSEcCtD
Pramipexole—Pain—Epirubicin—ovarian cancer	0.000154	0.000168	CcSEcCtD
Pramipexole—Constipation—Epirubicin—ovarian cancer	0.000154	0.000168	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000152	0.000166	CcSEcCtD
Pramipexole—Insomnia—Doxorubicin—ovarian cancer	0.00015	0.000164	CcSEcCtD
Pramipexole—Paraesthesia—Doxorubicin—ovarian cancer	0.000149	0.000163	CcSEcCtD
Pramipexole—Dyspnoea—Doxorubicin—ovarian cancer	0.000148	0.000162	CcSEcCtD
Pramipexole—Feeling abnormal—Epirubicin—ovarian cancer	0.000148	0.000162	CcSEcCtD
Pramipexole—Somnolence—Doxorubicin—ovarian cancer	0.000148	0.000162	CcSEcCtD
Pramipexole—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000147	0.000161	CcSEcCtD
Pramipexole—Dyspepsia—Doxorubicin—ovarian cancer	0.000146	0.00016	CcSEcCtD
Pramipexole—Decreased appetite—Doxorubicin—ovarian cancer	0.000145	0.000158	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000144	0.000157	CcSEcCtD
Pramipexole—Fatigue—Doxorubicin—ovarian cancer	0.000143	0.000157	CcSEcCtD
Pramipexole—Urticaria—Epirubicin—ovarian cancer	0.000143	0.000156	CcSEcCtD
Pramipexole—Pain—Doxorubicin—ovarian cancer	0.000142	0.000155	CcSEcCtD
Pramipexole—Constipation—Doxorubicin—ovarian cancer	0.000142	0.000155	CcSEcCtD
Pramipexole—Abdominal pain—Epirubicin—ovarian cancer	0.000142	0.000155	CcSEcCtD
Pramipexole—Body temperature increased—Epirubicin—ovarian cancer	0.000142	0.000155	CcSEcCtD
Pramipexole—Feeling abnormal—Doxorubicin—ovarian cancer	0.000137	0.00015	CcSEcCtD
Pramipexole—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000136	0.000149	CcSEcCtD
Pramipexole—Hypersensitivity—Epirubicin—ovarian cancer	0.000132	0.000145	CcSEcCtD
Pramipexole—Urticaria—Doxorubicin—ovarian cancer	0.000132	0.000144	CcSEcCtD
Pramipexole—Body temperature increased—Doxorubicin—ovarian cancer	0.000132	0.000144	CcSEcCtD
Pramipexole—Abdominal pain—Doxorubicin—ovarian cancer	0.000132	0.000144	CcSEcCtD
Pramipexole—Asthenia—Epirubicin—ovarian cancer	0.000129	0.000141	CcSEcCtD
Pramipexole—Pruritus—Epirubicin—ovarian cancer	0.000127	0.000139	CcSEcCtD
Pramipexole—Diarrhoea—Epirubicin—ovarian cancer	0.000123	0.000134	CcSEcCtD
Pramipexole—Hypersensitivity—Doxorubicin—ovarian cancer	0.000123	0.000134	CcSEcCtD
Pramipexole—Asthenia—Doxorubicin—ovarian cancer	0.000119	0.00013	CcSEcCtD
Pramipexole—Dizziness—Epirubicin—ovarian cancer	0.000119	0.00013	CcSEcCtD
Pramipexole—Pruritus—Doxorubicin—ovarian cancer	0.000118	0.000129	CcSEcCtD
Pramipexole—Vomiting—Epirubicin—ovarian cancer	0.000114	0.000125	CcSEcCtD
Pramipexole—Diarrhoea—Doxorubicin—ovarian cancer	0.000114	0.000124	CcSEcCtD
Pramipexole—Rash—Epirubicin—ovarian cancer	0.000113	0.000124	CcSEcCtD
Pramipexole—Dermatitis—Epirubicin—ovarian cancer	0.000113	0.000124	CcSEcCtD
Pramipexole—Headache—Epirubicin—ovarian cancer	0.000113	0.000123	CcSEcCtD
Pramipexole—Dizziness—Doxorubicin—ovarian cancer	0.00011	0.00012	CcSEcCtD
Pramipexole—Nausea—Epirubicin—ovarian cancer	0.000107	0.000117	CcSEcCtD
Pramipexole—Vomiting—Doxorubicin—ovarian cancer	0.000106	0.000116	CcSEcCtD
Pramipexole—Rash—Doxorubicin—ovarian cancer	0.000105	0.000115	CcSEcCtD
Pramipexole—Dermatitis—Doxorubicin—ovarian cancer	0.000105	0.000114	CcSEcCtD
Pramipexole—Headache—Doxorubicin—ovarian cancer	0.000104	0.000114	CcSEcCtD
Pramipexole—Nausea—Doxorubicin—ovarian cancer	9.88e-05	0.000108	CcSEcCtD
Pramipexole—HTR1A—Signaling Pathways—CDKN1B—ovarian cancer	2.82e-06	0.000186	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	2.81e-06	0.000185	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	2.81e-06	0.000185	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	2.8e-06	0.000185	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CXCL8—ovarian cancer	2.79e-06	0.000184	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—AKT1—ovarian cancer	2.79e-06	0.000184	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MYC—ovarian cancer	2.79e-06	0.000184	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCND1—ovarian cancer	2.79e-06	0.000184	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—HRAS—ovarian cancer	2.77e-06	0.000183	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	2.77e-06	0.000183	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MAPK1—ovarian cancer	2.77e-06	0.000183	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—EGFR—ovarian cancer	2.77e-06	0.000183	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CASP3—ovarian cancer	2.76e-06	0.000182	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CTNNB1—ovarian cancer	2.76e-06	0.000182	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL2—ovarian cancer	2.76e-06	0.000182	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CASP3—ovarian cancer	2.75e-06	0.000181	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—ovarian cancer	2.74e-06	0.000181	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL2—ovarian cancer	2.74e-06	0.000181	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MAPK3—ovarian cancer	2.73e-06	0.00018	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—ovarian cancer	2.73e-06	0.00018	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CDKN1B—ovarian cancer	2.73e-06	0.00018	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—ovarian cancer	2.73e-06	0.00018	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MAPK1—ovarian cancer	2.73e-06	0.00018	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—EGFR—ovarian cancer	2.72e-06	0.00018	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—PIK3CA—ovarian cancer	2.72e-06	0.00018	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	2.71e-06	0.000179	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MMP9—ovarian cancer	2.7e-06	0.000178	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—STAT3—ovarian cancer	2.7e-06	0.000178	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—AKT1—ovarian cancer	2.7e-06	0.000178	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—NRAS—ovarian cancer	2.69e-06	0.000178	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—ovarian cancer	2.69e-06	0.000177	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCND1—ovarian cancer	2.69e-06	0.000177	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PTEN—ovarian cancer	2.69e-06	0.000177	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	2.68e-06	0.000177	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—PIK3CA—ovarian cancer	2.68e-06	0.000177	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCND1—ovarian cancer	2.67e-06	0.000176	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CASP3—ovarian cancer	2.67e-06	0.000176	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—ERBB2—ovarian cancer	2.67e-06	0.000176	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—KRAS—ovarian cancer	2.67e-06	0.000176	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL2—ovarian cancer	2.67e-06	0.000176	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—STAT3—ovarian cancer	2.66e-06	0.000176	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CTNNB1—ovarian cancer	2.66e-06	0.000176	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MYC—ovarian cancer	2.66e-06	0.000175	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NRAS—ovarian cancer	2.66e-06	0.000175	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—ovarian cancer	2.66e-06	0.000175	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	2.65e-06	0.000175	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	2.65e-06	0.000175	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CB—ovarian cancer	2.64e-06	0.000174	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MTOR—ovarian cancer	2.64e-06	0.000174	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	2.63e-06	0.000173	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	2.62e-06	0.000173	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—AKT1—ovarian cancer	2.62e-06	0.000173	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—KRAS—ovarian cancer	2.62e-06	0.000173	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MMP9—ovarian cancer	2.61e-06	0.000172	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCND1—ovarian cancer	2.6e-06	0.000172	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MAPK1—ovarian cancer	2.6e-06	0.000172	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—EGFR—ovarian cancer	2.6e-06	0.000172	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MMP9—ovarian cancer	2.6e-06	0.000171	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PTEN—ovarian cancer	2.6e-06	0.000171	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MTOR—ovarian cancer	2.59e-06	0.000171	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	2.59e-06	0.000171	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PTEN—ovarian cancer	2.58e-06	0.00017	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MAPK3—ovarian cancer	2.58e-06	0.00017	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CTNNB1—ovarian cancer	2.58e-06	0.00017	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—KRAS—ovarian cancer	2.57e-06	0.00017	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MAPK3—ovarian cancer	2.54e-06	0.000168	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CXCL8—ovarian cancer	2.53e-06	0.000167	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	2.53e-06	0.000167	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	2.53e-06	0.000167	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	2.52e-06	0.000166	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—HRAS—ovarian cancer	2.52e-06	0.000166	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	2.51e-06	0.000166	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MYC—ovarian cancer	2.51e-06	0.000165	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	2.49e-06	0.000165	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	2.48e-06	0.000163	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MYC—ovarian cancer	2.47e-06	0.000163	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	2.47e-06	0.000163	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—KRAS—ovarian cancer	2.46e-06	0.000162	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	2.45e-06	0.000162	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MAPK1—ovarian cancer	2.45e-06	0.000162	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—EGFR—ovarian cancer	2.45e-06	0.000162	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	2.45e-06	0.000162	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	2.45e-06	0.000162	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTEN—ovarian cancer	2.44e-06	0.000161	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	2.44e-06	0.000161	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	2.43e-06	0.000161	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	2.43e-06	0.00016	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CASP3—ovarian cancer	2.43e-06	0.00016	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL2—ovarian cancer	2.42e-06	0.00016	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MAPK1—ovarian cancer	2.42e-06	0.00016	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—EGFR—ovarian cancer	2.42e-06	0.00016	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—ovarian cancer	2.41e-06	0.000159	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	2.41e-06	0.000159	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	2.4e-06	0.000159	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	2.4e-06	0.000159	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	2.4e-06	0.000158	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	2.39e-06	0.000158	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CASP3—ovarian cancer	2.39e-06	0.000157	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL2—ovarian cancer	2.38e-06	0.000157	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TP53—ovarian cancer	2.37e-06	0.000157	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—ovarian cancer	2.37e-06	0.000156	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	2.37e-06	0.000156	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCND1—ovarian cancer	2.36e-06	0.000156	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	2.36e-06	0.000156	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	2.36e-06	0.000156	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	2.34e-06	0.000155	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	2.34e-06	0.000154	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	2.33e-06	0.000154	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TP53—ovarian cancer	2.33e-06	0.000153	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCND1—ovarian cancer	2.32e-06	0.000153	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—STAT3—ovarian cancer	2.32e-06	0.000153	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—KRAS—ovarian cancer	2.32e-06	0.000153	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NRAS—ovarian cancer	2.32e-06	0.000153	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—STAT3—ovarian cancer	2.31e-06	0.000152	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NRAS—ovarian cancer	2.3e-06	0.000152	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	2.3e-06	0.000152	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	2.3e-06	0.000152	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MMP9—ovarian cancer	2.29e-06	0.000151	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TP53—ovarian cancer	2.29e-06	0.000151	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—KRAS—ovarian cancer	2.29e-06	0.000151	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PTEN—ovarian cancer	2.28e-06	0.00015	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—HRAS—ovarian cancer	2.27e-06	0.00015	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	2.27e-06	0.00015	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	2.27e-06	0.00015	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	2.26e-06	0.000149	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MMP9—ovarian cancer	2.26e-06	0.000149	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	2.25e-06	0.000149	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	2.25e-06	0.000148	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PTEN—ovarian cancer	2.24e-06	0.000148	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	2.24e-06	0.000148	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MYC—ovarian cancer	2.23e-06	0.000147	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—HRAS—ovarian cancer	2.22e-06	0.000147	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—AKT1—ovarian cancer	2.22e-06	0.000147	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	2.22e-06	0.000146	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	2.22e-06	0.000146	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	2.21e-06	0.000146	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	2.19e-06	0.000145	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—HRAS—ovarian cancer	2.19e-06	0.000144	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	2.19e-06	0.000144	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	2.19e-06	0.000144	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	2.19e-06	0.000144	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TP53—ovarian cancer	2.18e-06	0.000144	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PIK3CA—ovarian cancer	2.18e-06	0.000144	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—ovarian cancer	2.17e-06	0.000143	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	2.17e-06	0.000143	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL2—ovarian cancer	2.17e-06	0.000143	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	2.16e-06	0.000142	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MYC—ovarian cancer	2.16e-06	0.000142	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	2.15e-06	0.000142	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MYC—ovarian cancer	2.15e-06	0.000142	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	2.13e-06	0.00014	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—ovarian cancer	2.13e-06	0.00014	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PIK3CA—ovarian cancer	2.12e-06	0.00014	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	2.11e-06	0.000139	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	2.11e-06	0.000139	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—EGFR—ovarian cancer	2.11e-06	0.000139	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	2.1e-06	0.000139	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	2.1e-06	0.000138	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—EGFR—ovarian cancer	2.1e-06	0.000138	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—ovarian cancer	2.09e-06	0.000138	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	2.09e-06	0.000138	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—HRAS—ovarian cancer	2.09e-06	0.000138	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MYC—ovarian cancer	2.09e-06	0.000138	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	2.06e-06	0.000136	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TP53—ovarian cancer	2.06e-06	0.000136	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—ovarian cancer	2.06e-06	0.000136	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	2.05e-06	0.000135	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	2.04e-06	0.000135	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	2.04e-06	0.000135	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	2.04e-06	0.000135	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—STAT3—ovarian cancer	2.04e-06	0.000134	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NRAS—ovarian cancer	2.03e-06	0.000134	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TP53—ovarian cancer	2.03e-06	0.000134	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PIK3CA—ovarian cancer	2.03e-06	0.000134	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	2.03e-06	0.000134	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—AKT1—ovarian cancer	2.01e-06	0.000132	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—STAT3—ovarian cancer	2.01e-06	0.000132	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NRAS—ovarian cancer	2e-06	0.000132	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—ovarian cancer	2e-06	0.000132	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—KRAS—ovarian cancer	1.99e-06	0.000131	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	1.99e-06	0.000131	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.98e-06	0.000131	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—HRAS—ovarian cancer	1.97e-06	0.00013	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—AKT1—ovarian cancer	1.96e-06	0.00013	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MAPK3—ovarian cancer	1.95e-06	0.000128	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—HRAS—ovarian cancer	1.94e-06	0.000128	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—AKT1—ovarian cancer	1.93e-06	0.000127	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	1.93e-06	0.000127	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.92e-06	0.000126	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	1.9e-06	0.000125	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MYC—ovarian cancer	1.89e-06	0.000125	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—ovarian cancer	1.89e-06	0.000124	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.86e-06	0.000123	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—ovarian cancer	1.86e-06	0.000123	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MAPK1—ovarian cancer	1.85e-06	0.000122	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—EGFR—ovarian cancer	1.85e-06	0.000122	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—AKT1—ovarian cancer	1.84e-06	0.000122	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.84e-06	0.000122	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TP53—ovarian cancer	1.83e-06	0.000121	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	1.83e-06	0.000121	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.82e-06	0.00012	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.82e-06	0.00012	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.82e-06	0.00012	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.82e-06	0.00012	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.82e-06	0.00012	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—AKT1—ovarian cancer	1.78e-06	0.000117	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	1.77e-06	0.000117	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TP53—ovarian cancer	1.77e-06	0.000117	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.76e-06	0.000116	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	1.75e-06	0.000116	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—KRAS—ovarian cancer	1.75e-06	0.000115	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	1.74e-06	0.000115	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—AKT1—ovarian cancer	1.74e-06	0.000115	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—AKT1—ovarian cancer	1.73e-06	0.000114	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—KRAS—ovarian cancer	1.72e-06	0.000114	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CA—ovarian cancer	1.72e-06	0.000114	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—AKT1—ovarian cancer	1.72e-06	0.000113	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TP53—ovarian cancer	1.71e-06	0.000113	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MYC—ovarian cancer	1.7e-06	0.000112	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—HRAS—ovarian cancer	1.69e-06	0.000112	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—HRAS—ovarian cancer	1.69e-06	0.000111	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—ovarian cancer	1.68e-06	0.000111	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—AKT1—ovarian cancer	1.66e-06	0.000109	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	1.66e-06	0.000109	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	1.66e-06	0.000109	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	1.64e-06	0.000108	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—ovarian cancer	1.62e-06	0.000107	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—ovarian cancer	1.61e-06	0.000106	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	1.61e-06	0.000106	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	1.58e-06	0.000104	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—ovarian cancer	1.57e-06	0.000104	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	1.57e-06	0.000103	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TP53—ovarian cancer	1.56e-06	0.000103	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	1.55e-06	0.000102	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TP53—ovarian cancer	1.53e-06	0.000101	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—AKT1—ovarian cancer	1.5e-06	9.87e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—AKT1—ovarian cancer	1.49e-06	9.82e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—HRAS—ovarian cancer	1.49e-06	9.81e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—HRAS—ovarian cancer	1.46e-06	9.65e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	1.45e-06	9.55e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	1.44e-06	9.49e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—ovarian cancer	1.42e-06	9.39e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—AKT1—ovarian cancer	1.41e-06	9.28e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—ovarian cancer	1.4e-06	9.24e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TP53—ovarian cancer	1.39e-06	9.18e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	1.33e-06	8.78e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT1—ovarian cancer	1.31e-06	8.66e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT1—ovarian cancer	1.29e-06	8.53e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—ovarian cancer	1.27e-06	8.41e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	1.18e-06	7.76e-05	CbGpPWpGaD
